Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients by Ventura-Cots, Meritxell et al.
Therapeutic Advances in Gastroenterology
Ther Adv Gastroenterol
2016, Vol. 9(6) 823 –835
DOI: 10.1177/ 
1756283X16658252
© The Author(s), 2016. 
Reprints and permissions:  
http://www.sagepub.co.uk/
journalsPermissions.nav
http://tag.sagepub.com 823
Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/
licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the 
SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Hepatic encephalopathy (HE) is a major compli-
cation of cirrhosis associated with high mortality 
and poor quality of life [Ferenci et al. 2002]; it 
also carries a high economic and social burden 
[Patel et al. 2012; Stepanova et al. 2012]. Multiple 
risk factors have been classically associated with 
the development of HE, including upper gastroin-
testinal bleeding (UGIB). UGIB induces a status 
of hyperammonemia through the intraluminal 
digestion of blood-nitrogenous compounds by 
colonic bacteria. In addition, the catabolic status 
caused by gastrointestinal bleeding provokes an 
increase in ammoniagenesis in different tissues 
[Olde Damink et  al. 2003]. Ammonia and its 
transformation to glutamine in the astrocyte 
appear to be a key factor in HE development and 
pathogenesis [Albrecht and Norenberg, 2006; 
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Abstract
Background: Ornithine phenylacetate (OP) has been proven effective in lowering ammonia 
plasma levels in animals, and to be well tolerated in cirrhotic patients. A trial to assess OP 
efficacy in lowering plasma ammonia levels versus placebo in cirrhotic patients after an upper 
gastrointestinal bleeding was performed. The primary outcome was a decrease in venous 
plasma ammonia at 24 hours.
Methods: A total of 38 consecutive cirrhotic patients were enrolled within 24 hours of an upper 
gastrointestinal bleed. Patients were randomized (1:1) to receive OP (10 g/day) or glucosaline 
for 5 days.
Results: The primary outcome was not achieved. A progressive decrease in ammonia was 
observed in both groups, being slightly greater in the OP group, with significant differences 
only at 120 hours. The subanalysis according to Child–Pugh score showed a statistically 
significant ammonia decrease in Child–Pugh C-treated patients at 36 hours, as well as in the 
time-normalized area under the curve (TN-AUC) 0–120 hours in the OP group [40.16 μmol/l 
(37.7–42.6); median (interquartile range) (IQR)] versus placebo group [65.5 μmol/l (54–126); 
p = 0.036]. A decrease in plasma glutamine levels was observed in the treated 
group compared with the placebo group, and was associated with the appearance of 
phenylacetylglutamine in urine. Adverse-event frequency was similar in both groups. No 
differences in hepatic encephalopathy incidence were observed.
Conclusions: OP failed to significantly decrease plasma ammonia at the given doses  
(10 g/day). Higher doses of OP might be required in Child–Pugh A and B patients. OP appeared 
well tolerated.
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Butterworth, 2003; Shawcross et al. 2005]. Current 
strategies for the treatment of HE have been 
focused on lowering ammonia production through 
the administration of nonabsorbable disaccharides 
(NADs) or antibiotics. These therapies have been 
proved to be effective in HE primary and second-
ary prophylaxis [Agrawal et  al. 2012; Bass et  al. 
2010; Sharma et al. 2012], but no effects on overt 
HE episodes or in survival have been shown [Als-
Nielsen et al. 2004; Bass et al. 2010], except for 
rifaximin, with promising results in overt HE, but 
with a short period of follow up [Sharma et  al. 
2013]. Other strategies are based on promoting 
ammonia elimination; glycerol phenylbutyrate has 
proved its efficacy in secondary prophylaxis, but it 
has not been tested in cirrhotic-decompensated 
patients [Rockey et al. 2014]. Ornithine phenylac-
etate (OP) is a new drug proposed as an ammonia 
scavenger. This therapy is based on the capacity of 
ornithine to stimulate the activity of glutamine 
synthetase, hence incorporating ammonia into a 
‘nontoxic’ molecule. The newly formed glutamine 
will combine with phenylacetate (PA), allowing 
the elimination of ammonia in the urine by its 
conversion into phenylacetylglutamine (PAGN). 
This strategy prevents the degradation of glu-
tamine by intestinal glutaminase and avoids new 
formation of ammonia [Jalan et  al. 2007]. OP 
has been proven to be effective in animal models 
[Oria et al. 2012] and well tolerated in cirrhotic-
decompensated patients [Ventura-Cots et  al. 
2013]. OP has been evaluated in a phase I study 
conducted in healthy volunteers, as well as in a 
phase IIa study in patients with stable hepatic cir-
rhosis. The results confirmed that OP was well 
tolerated and had linear pharmacokinetics at doses 
up to 10 g infused over 4–24 hours [Hassanein 
et  al. 2012]. Although our prior data supported 
the concept that this molecule might be effective 
in lowering ammonia [Ventura-Cots et al. 2013], 
no randomized clinical trial compared with pla-
cebo had been performed. The goal of the current 
study was to confirm the efficacy of OP in lower-
ing plasma ammonia in patients with cirrhosis and 
UGIB, a relevant clinical scenario associated with 
high mortality and important complications [de 
Franchis, 2010; Garcia-Tsao and Bosch, 2010].
Methods
The study was a randomized, double-blind, pla-
cebo-controlled, multicenter study comparing the 
efficacy of OP versus placebo in cirrhotic patients 
with UGIB. Thirty-eight consecutive patients 
recruited from September 2012 to August 2014 
admitted to the Hospital Vall d’Hebron and 
Hospital de la Santa Creu i Sant Pau (both in 
Barcelona) were included. A block size of 10 was 
used to randomize patients; randomization was 
also stratified by the centers.
The Institutional Review Boards at the study site 
and the Spanish Agency of Medications and 
Sanitary Products approved the study according 
to the World Medical Association’s Declaration 
of Helsinki. Written informed consent was 
obtained from subjects prior to enrolment. This 
study is a registered trial [ClinicalTrials.gov 
identifier: NCT01434108; EudraCT number: 
2009-017819-16].
Patient selection
Subjects were eligible for inclusion if they met the 
following criteria: age between 18 and 85 years, 
had a diagnosis of cirrhosis as defined by clinical, 
laboratory or radiological findings and experi-
enced a UGIB that was active within 24 hours 
prior to inclusion.
Subjects were excluded from enrolment if they 
exhibited one of the following criteria: need of 
mechanical ventilation, terminal illness, infection 
by human immunodeficiency virus, neurological 
comorbidities that impaired mental status, sus-
pected hypersensitivity or allergic reaction to the 
drug components, electrocardiogram with QTcF 
> 500ms (Bazzet formula), creatinine > 1.5 mg/dl 
or need for hemodialysis. Additional causes of 
exclusion were the use of the following drugs: 
penicillin, probenecid, haloperidol, valproic acid, 
and systemic corticosteroids (because of their 
potential interaction with the study drug) and 
rifaximin (per protocol). In premenopausal 
women, a negative result in pregnancy test was 
required and breastfeeding was forbidden.
Study protocol
Patients were admitted to a semi-intensive care 
unit (Bleeding Unit) for at least 48 hours, until 
clinical stability was established. After this period 
of time, patients were transferred to a general-
medicine ward. The standard protocol for the 
management of UGIB included: intravenous flu-
ids (glucose and saline), perfusion of somatosta-
tin (6 mg/24 hours), use of broad-spectrum 
antibiotics (ceftriaxone 1 g/daily, intravenously), 
omeprazole (20 mg/12 hours), nasogastric aspira-
tion of blood and lactulose (initially as enema/12 
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hours; later orally, adjusted to 2–3 bowel move-
ments/day). The use of rifaximin was prohibited 
as per protocol. Upper gastrointestinal endoscopy 
was performed during the first 24 hours and ther-
apy was administered according to findings.
Study medication was prepared in 200 ml empty 
flasks (10 g/50 ml vials of OP diluted in 150 ml 
vials of sterile water for injection, or placebo, 200 
ml glucose–saline solution) by the pharmacy 
department and blindly delivered to the study 
investigators. Medication was administered as an 
intravenous-continuous infusion, at 0.416 g/h for 
5 days (10 g/day), provided the patients did not 
develop a stopping or withdrawal criteria. In addi-
tion, 1 day was required to carry out a clinical and 
biochemical assessment, and finally, a follow up 
at 28 days was performed.
Blood samples (10 ml) were collected every 12 
hours during the first 48 hours and daily thereaf-
ter (up to day 6). A venous access was chosen to 
avoid discomfort to patients and because venous 
ammonia shows a good correlation with arterial 
ammonia [Ong et al. 2003]. Urinary samples were 
collected every 12 hours during the first 48 hours 
and daily thereafter (up to day 6). Complete urine 
collection was obtained via urinary catheter dur-
ing the first 48 hours and by supervised 24-hour 
urine collection after catheter removal.
A follow up at day 28 was performed. Blood sam-
ples were centrifuged within 15 minutes of sam-
pling and stored frozen at −80ºC.
Outcomes
The primary outcome was a decrease in average 
venous plasma ammonia at 24 hours. Secondary 
outcomes included: changes in plasma amino 
acids and ammonia between both groups at any 
timepoint; pharmacokinetic profiles of PA and 
ornithine in plasma, and PAGN in urine in order 
to explore mechanistic processes; HE [presence, 
duration and severity measured by the West 
Haven and Clinical Hepatic Encephalopathy 
Staging Scale (CHESS) scales]; bacterial infec-
tions during treatment period; and safety and tol-
erability of OP.
Analytical procedures
Ammonia was collected in refrigerated tubs, 
stored in ice until centrifugation (15 minutes, 
3000 rpm, 4ºC), and frozen at −80ºC; the whole 
process was always performed in less than 15 
minutes. Ammonia and amino-acid measure-
ments were centralized in hospital Vall d’Hebron 
and performed in the Laboratory of Metabolic 
Diseases. Standard laboratory tests included: 
hemogram, reticulocyte count, prothrombine 
time and bilirubin, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alka-
line phosphatase, albumin, sodium, potassium, 
creatinine and calcium plasma concentration.
Ammonia was measured in a Cobas 6000 ana-
lyzer (Roche Diagnostics Indianapolis, IN, USA) 
by standard methodology. Physiologic-free amino 
acids were analyzed as aminoquinoline deriva-
tives by reverse-phase ultra-performance liquid 
chromatography (UPLC), Acquity-UPLC 
(AccQ-Tag chemistry, MassTrak AAA method 
and instruments, Waters, Milford, MA, US), 
using a binary solvent gradient at 42.5ºC and 
spectrophotometric detection at 260 nm follow-
ing manufacturer instructions. Prior to derivatiza-
tion and chromatography, an internal standard 
(norvaline) was added and samples were depro-
teinized by ultrafiltration [Narayan et  al. 2011]. 
PA and PAGN were analyzed by liquid chroma-
tography–tandem mass spectrometry according 
to the protocol set out by Laryea and colleagues 
[Laryea et al. 2010], with some modifications. PA 
and PAGN were analyzed by liquid chromatogra-
phy–tandem mass spectrometry. (a) Reagents: 
deuterium-labeled internal-standard [N-(phenyl-
d5-acetyl)-L-glutamine] (d5-PAG) (CDN iso-
topes, Pointe Claire, QB, Canada). (b) Sample 
preparation. (1) Standards: the calibration curve 
was prepared by diluting stock solutions of each 
standard with MiliQ water to cover a 0–12.92 
µmol of PA and 0–32.30 µmol of PAGN concen-
tration range, adding d5-PAGN as internal stand-
ard (until 3.5 µmol final), in conical plastic 
centrifuge tubes. (2) Plasma: 100 µl diluted 1:5 
plasma was mixed with d5-PAGN (as in stand-
ards) and was ultrafiltered (10,000g × 30 min-
utes). (3) Urine: 100 µl 0.22 µmol filtered urine 
was diluted 1:200 with MiliQ water and mixed 
with d5-PAGN (as in standards). (c) Liquid 
chromatography–tandem mass spectrometry: 
instrumentation consisted of an Acquity-UPLC 
separation module (Waters, Milford, MA, USA) 
coupled to a Xevo TQ mass-spectrometry system 
with the Mass Lynx software (Waters, Manchester, 
UK). The analytical column was an Acquity-
UPLC HSS C18 (2.1 mm × 100 mm). Sample 
elution was achieved by a 3-minute mobile-phase 
linear gradient consisting of an initial 40% solvent 
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A (methanol) and 60% solvent B (1% formic acid 
in water), changing to 80% solvent A and 20% B 
from 0–2 minutes, back to 40% solvent A/60% B 
from 2–2.1 minutes, and equilibrating with these 
conditions from 2.1–3 minutes. Some 5 µl super-
natant samples were injected into the system and 
the column temperature was maintained at 40ºC. 
Conditions for the mass-spectrometry analysis 
were: the ionization mode was a negative electro-
spray (ESI−); capillary voltage was 3kV; desolva-
tion gas, heated to 450ºC and delivered at a flow 
rate of 1100 l/h; and cone-gas flow (argon) was 
0.15 ml/min. Multiple reaction-monitoring transi-
tions were optimized at the following conditions: 
dwell time: 0.073 seconds, PAGN: precursor ion 
263 (m/z), product ion 145 (m/z), cone voltage 30 
V, collision energy 15 eV; PA: precursor ion 135 
(m/z), product ion 91 (m/z), cone voltage 20 V, 
collision energy 10 eV; d5-PAGN: precursor ion 
268 (m/z), product ion 145 (m/z), cone voltage 
30 V, collision energy 20 eV.
Clinical evaluation
Patients were evaluated at the time of initial infu-
sion, every 12 hours during the first 2 days and 
every day thereafter until day 6; a follow up visit 
was performed 1 month later. The clinical exam 
included a 12-lead electrocardiogram, any com-
plications related to cirrhosis, vital signs, and the 
presence of bacterial infections. The presence of 
HE was evaluated throughout the study with 
West-Haven criteria [Conn et al. 1977] and the 
CHESS [Ortiz et al. 2007].
Data analysis
The total sample size of 38 patients (17 patients 
per group plus 10% of losses) was calculated to 
detect a difference of 25 ± 25 standard deviation 
(SD) μmol/l in the mean ammonia average 
between the two groups at 24 hours (80% power 
using a one-sided test with alpha = 0.05).
The clinical trial data were independently moni-
tored by the Academic Research Organization of 
the Vall d’Hebron Institute of Research. A sta-
tistical analysis plan was defined between the 
statistician of the Unit of Statistics and 
Bioinformatics of Vall d’Hebron Institute of 
Research and the study investigators before the 
conclusion of the study. A data-blind review was 
conducted between the monitors, the statistician 
and the study investigators before locking the 
trial database. The statistical analysis was carried 
out with Stata 13.1. Descriptive statistics were 
used to summarize the data. Quantitative varia-
bles were described as mean ± standard deviation 
for normally distributed variables or median and 
interquartile range if normality criteria were not 
met. Normality was assessed by Shapiro-Wilk 
test and quantitative variables were compared 
using the one-sided Wilcoxon Rank Sum Test. 
Percentages were calculated for categorical data. 
Qualitative variables were described as frequency 
and percentage, and the one-sided Fisher’s exact 
test was used for calculation. The Wilcoxon Rank 
Sum Test was used to compare the duration and 
severity of HE. Ammonia profile and changes 
were calculated with time-normalized area under 
the curve through 120 hours (TN-AUC0–120h). 
Subject’s regression slopes and group compari-
sons were made using a one-sided Wilcoxon Rank 
Sum test.
Results
Characteristics of patients
A total of 110 patients were assessed for eligibil-
ity; 72 were excluded for different reasons. The 
main reason for not participating was age, fol-
lowed by a creatinine level higher than 1.5 mg/dl. 
Two patients had to be withdrawn from the study, 
one of them on day 5 because of a severe adverse 
event and the other because of a rebleeding dur-
ing the first 12 hours (Figure 1).
Most of the patients in both groups were males, 
with a mean age of 55 years. Groups differed in cir-
rhosis etiology (70% alcohol in the OP group versus 
44.4% in the placebo group, and 5.5% of hepatitis 
C virus in the OP versus 33.3% in the placebo 
group). Most of the patients in both groups 
belonged to Child–Pugh class B, with similar 
Model for End-stage Liver Disease (MELD) 
scores. All patients in both groups had presented 
with previous liver decompensation, being the most 
common UGIB, followed by ascites. Only one 
patient in the placebo group and two in the OP 
group had previously developed overt HE. At 
inclusion, ascites was the most frequent decom-
pensation event (30% in the OP group versus 22.2% 
in placebo group), followed by HE; no bacterial 
infections were observed (Table 1). Hematological 
and biochemical parameters were in accordance of 
what is expected during a UGIB and no differences 
between groups were seen at baseline.
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Primary outcome
The primary outcome was not achieved. OP 
failed to significantly decrease plasma ammonia 
at the given doses. A progressive decrease in 
ammonia was observed in both groups, being 
slightly greater in the OP group, with significant 
differences only at 120 hours (Figure 2). Although 
the decrease in ammonia at 24 hours in the OP 
group [−20.4 µmol/l (−39.20 to −2.80); median 
(IQR)] was almost twice that observed in the pla-
cebo group [−11.88 µmol/l (−36.75 to −26.35)], 
differences did not reach statistical significance. 
The subanalysis by Child–Pugh class showed a 
statistically significant ammonia decrease in Child 
C-treated patients at 36 hours (p = 0.018), as 
well as in the TN-AUC0–120h in the OP group 
[40.16 μmol/l (37.7−42.6)] versus placebo group 
[65.5 μmol/l (54−126); p = 0.024] (Table 2). 
However, the number of patients in this subgroup 
analysis was very small.
Other analytical parameters
A progressive decrease in glycine and glutamine 
was observed in the treated group as compared 
with the placebo group, reaching a peak at day 5 
in both cases. Differences between both groups 
started at the 24-hour point and were maintained 
thereafter (Figure 3). Plasma PA levels differed 
between groups during the entire study (Table 3), 
the TN-AUC0–120h in the placebo group was 1.6 
μmol/l (0.7−3.3) versus 111.6 μmol/l (63.5−148.5) 
in the OP group (p < 0.05). Once the 36-hour 
dose was reached, PA levels in the OP group 
remained stable until the end of infusion, never 
achieving the toxic values that have been reported 
at a much higher range (approximately 7000 
μmol/l) [Thibault et  al. 1994]. Urinary levels of 
PAGN, the main elimination pathway of OP, 
showed remarkable differences between both 
groups (Table 3). Total amount of PA excretion 
accounted for 87% of PA administered as OP at 
the end of the study.
Clinical outcome
Per standard of care, all patients underwent an 
upper gastrointestinal endoscopy during the first 
24 hours of admission. The main cause for UGIB 
in both groups was esophageal variceal bleeding 
(45% OP versus 83.3% placebo; p = 0.1); all of 
these patients underwent drug treatment and 
variceal ligation. In the OP group, duodenal or 
gastric ulcers were frequent etiologies and suitable 
endoscopic therapies were performed. Three 
patients in the placebo group and seven in the OP 
Figure 1. Flow chart of patient selection.
SAE, severe adverse event; HIV, human immunodeficiency virus; OP, ornithine phenylacetate; QTC, corrected QT interval. 
*Withdrawal at day 5, data from the first 5 days included in the study.
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Table 1. Characteristics of patients treated with ornithyne phenylactetate and placebo.
Placebo
n = 18
OP
n = 20
Demographics  
Age, mean (SD) 56 (11) 55 (10)
Gender (male), n (%) 12 (66%) 14 (70%)
Cirrhosis etiology, n (%)  
Alcohol 8 (44.4%) 14 (70%)
HCV 6 (33.3%) 1 (5%)
HCV & Alcohol 1 (5.6%) 2 (10%)
Other 3 (16.7%) 3 (15%)
Previous decompensation, n (%)  
Ascites 6 (33.3%) 9 (45%)
HE 4 (22.2%) 3 (15%)
SBP     0 2 (10%)
Hepatocarcinoma 1 (5.6%) 1 (5%)
UGIB 6 (33.3%) 8 (40%)
Child–Pugh at inclusion, n (%)  
A 3 (16.7%) 4 (20%)
B 9 (50%) 13 (52.7%)
C 6 (33.3%) 3 (15%)
MELD score at inclusion, mean (SD) 12.2 (3.9) 11.6 (4.4)
Current decompensation, n (%)  
Ascites 4 (22.2%) 6 (30%)
HE 3 (16.3%) 3 (15%)
SBP     0 0
Hepatocarcinoma 1 (5.6%) 1 (5%)
Hepatorenal syndrome     0     0
Analytical parameters, mean (SD)  
Hb (g/dl) 8.7 (1.7) 8.8 (1.7)
Leukocytes x109/l 7.7 (3.3) 8.5 (3.4)
Platelets x109/l 98.5 (39.4) 92.1 (44.4)
INR 1.56 (0.26) 1.59 (0.44)
Bilirubin (mg/dl) 2 (1.3) 2.2 (1.33)
ALT (IU/l) 65.8 (91.5) 57.1 (45)
AST (IU/l) 107 (179) 81.9 (57.5)
Creatinine (mg/dl) 0.78 (0.31) 0.88 (0.24)
Albumin (g/dl) 2.9 (0.58) 2.6 (0.54)
Alkaline phosphatase (IU/l) 111.8 (59.6) 114.8 (103)
γ-glutamil transpeptidase (IU/l) 183.3 (178.6) 158.1 (179)
Na (mEq/l) 139.9 (3.7) 137.3 (6)
Ammonia (μmol/l) 100.3 (43) 94.7 (47)
Vital signs, mean (SD)  
Systolic blood pressure (mmHg) 110 (17) 121 (21)
Dyastolic blood pressure (mmHg) 62.5 (11) 63 (11)
Heart rate (bpm) 79 (13) 80 (15)
Temperature (ºC) 36.4 (0.5) 36.4 (0.5)
ECG QTc (millisec) 416 (43) 422 (33)
Red-cell transfusion (units), median (range) 2 (0–4) 2.5 (0–4.5)
OP, ornithyne phenylactetate; HCV, hepatitis C virus; HE, hepatic encephalopathy; SBP, spontaneous bacterial peritonitis; 
SD, standard deviation; UGIB, upper gastrointestinal bleeding; Hb, hemoglobin; INR, international normalized ratio; ALT, 
Alanine transaminase; AST, Aspartate transaminase; Na, sodium; ECG, electrocardiogram; QTc corrected QT interval. 
Differences were not significant in any parameter except for HCV etiology; p < 0.05.
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group did not require endoscopic treatment. Only 
one patient in the OP group presented with 
rebleeding during the first 24 hours and under-
went a transjugular intrahepatic portosystemic 
shunt. Nine patients in the placebo group and 12 
in the OP group required blood transfusion; no 
difference between the total number of blood units 
transfused and the initial hemoglobin levels were 
observed between both groups (Table 1). The 
exposure to blood in the digestive tract was similar 
for both groups, since the ratio of isoleucine/(leu-
cine plus valine), a good parameter for estimation 
of the amount of blood ingested, showed no differ-
ences between groups (Supplementary Figure 1) 
[Dejong et al. 1996; Olde Damink et al. 1997].
Ascites was the most frequent decompensation 
event at inclusion: four patients in the placebo 
group and six in the OP group. Interestingly, 
three patients in the placebo group and none in 
the OP group developed ascites during the study.
Three patients in each group exhibited HE at 
inclusion. The median time of resolution was 
Figure 2. Plasma ammonia-concentration evolution during the study period in the ornithine phenylacetate 
and placebo groups.
Data are mean and one-sided standard deviation. Numbers at each timepoint indicate the number of patients with plasma 
samples analyzed.
FU, follow up.
*p < 0.05, mean ammonia in treated group at 120 hours was significantly lower than placebo group.
Table 2. Ammonia levels expressed as time normalized area under the curve from 0 to 120 hours (TN-AUC0–120h) 
of treated and control patients distributed by Child–Pugh score.
Ammonia μmol/l TN-AUC0–120h
Median (IQR) p value
Child–Pugh A Placebo n = 3 OP n = 4 0.571
 59.69 (56.73−111.80) 62.29 (57.82−70.47)  
Child–Pugh B Placebo n = 9 OP n = 13 0.486
 75.79 (59.48−84.94) 72.74 (46.86−90.26)  
Child–Pugh C Placebo n = 6 OP n = 3 0.024
 65.50 (53.97−125.76) 42.57 (37.76−51.09)  
OP; Ornithine phenylacetate, IQR; interquartile range.
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24 hours in both groups. One patient in the OP 
group presented with HE grade III, and two with 
grade II, while in the placebo group, all patients 
had HE grade II. During infusion time, two 
patients in the placebo group (grade II and grade 
III) and one in the OP group developed HE 
(grade I). Lactulose exposure during the study 
was 90% in the placebo group and 95% in the OP 
group.
Only one patient in the placebo group presented 
with a bacterial infection (pneumonia because of 
Figure 3. Glutamine (A) and glycine (B) plasma levels in treated and placebo patients.
FU, follow up.
Data are mean and one-sided standard deviation; numbers at each timepoint indicate the number of patients with plasma 
samples analyzed.
*p < 0.05.
M Ventura-Cots, M Concepción et al.
http://tag.sagepub.com 831
bronchial aspiration, secondary to the endoscopic 
procedure).
Safety and tolerability
The incidence of adverse events reported during 
the study was similar between the OP group 
(44.72%) and the placebo group (55.28%), as 
they were the more common adverse events 
(Table 4). Only one adverse event (nausea) in the 
OP group was considered related to medication. 
Ten severe adverse events were reported during 
the study: four in the placebo group and six in the 
OP group. Only three of these events were 
reported during drug infusion: one in the OP 
group and two in the placebo group (Table 5).
Discussion
Based on the results of the present study, OP was 
not able to obtain a significant decrease in ammo-
nia levels at 24 hours of therapy compared with 
placebo, and consequently failed to achieve the 
primary endpoint.
OP has proven safe and well tolerated in cirrhotic-
decompensated patients [Ventura-Cots et  al. 
2013] and preclinical studies have shown its 
potential effect in lowering plasma ammonia 
[Oria et al. 2012]. Although the trial was not suc-
cessful in reaching this goal, mean ammonia lev-
els were lower at every timepoint in the OP group, 
with statistically significant differences at 120 
hours. In addition, the TN-AUC0–120h was signifi-
cantly lower in the Child–Pugh C patients of the 
OP group compared with the placebo group, 
showing differences of 13.4µmol/l between 
groups. Differences of this magnitude been previ-
ously described as clinically significant (has been 
proven effective in decreasing the incidence of 
HE) in HE secondary-prophylaxis studies 
[Agrawal et  al. 2012; Rockey et  al. 2014]. 
However, the data obtained in Child–Pugh C 
patients should not be considered definitive, since 
the total number of Child–Pugh C patients 
included was very low.
Similarly to our prior safety and tolerability study 
[Ventura-Cots et  al. 2013], only patients with 
baseline plasma ammonia above the upper nor-
mal limit (⩾50 µmol/l) seem to obtain benefit 
from ammonia-scavenging drugs. It is important 
to consider the great individual variability in 
ammonia levels, not only in the OP group, but 
also in the placebo group. This variability has 
been previously described in healthy subjects, 
patients with urea-cycle disorders and patients 
with hepatic disease [Mokhtarani et  al. 2013], 
Table 3. Levels of phenylacetate in plasma, accumulated phenylacetylglutamine in urine (PAGNU), PAGNU 
adjusted to creatinine and percentage of PA eliminated in urine in patients treated with ornithine phenylacetate 
and placebo.
PAP
μmol/l
Mean (SD)
PAGNU accumulated
mmol
Mean (SD)
PAGN/CreatinineU
mmol/mol
Mean (SD)
% PA eliminated 
in urine**
Molar ratio***
 Placebo | OP Placebo | OP Placebo | OP OP
Baseline 3.5 (7.7) | 2.3 (3.4)  
12h 2.2 (3.3) | 89 (52.1)* 1.7 (1.7) | 13.5 (9.6)* 325 (287) | 2338 (904)* 59
24h 1.3 (2.3) | 125.4 (91.9)* 3.1 (2.8) | 33.5 (17.2)* 329 (367) | 3497 (1084)* 73
36h 0.8 (1) | 181.2 (168.4)* 3.8 (3.4) | 50.6 (24.1)* 163 (220) | 3776 (2723)* 74
48h 1.1 (1.8) | 149.2 (96.2)* 4.9 (4.3) | 76.6 (32.4)* 178 (287) | 3513 (1591)* 84
72h 0.6 (0.8) | 140.7 (130.9)* 6 (4.8) | 120 (51)* 125 (172) | 3571 (952)* 91
96h 0.9 (1.54) | 140 (112.2)* 8.3 (7.9) | 160 (67.6)* 191 (328) | 3764 (1560)* 92
120h 1.1 (1.8) | 110.5 (131.4)* 9.5 (9.8) | 190 (85)* 178 (232) | 3177 (1400)* 87
144h 0.74 (1.1) | 0.93 (0.9) 10.6 (11.2) | 200 (90)* 130 (175) | 284 (672)* –
OP, ornithyne phenylactetate; PA, phenylacetate; PAP, phenylacetate in plasma; PAGNU, accumulated phenylacetylgluta-
mine in urine; CreatinineU, creatinine in urine; SD, standard deviation.
*p < 0.05, OP group compared with placebo.
**In OP group only.
*** Molar ratios were calculated by dividing PAGNU accumulated (mmol) by OP administered (mmol), considering that 1 
mol of PAGN results from 1 mol of PA (or OP).
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Table 4. Most frequent adverse events and severe adverse events in the treated (ornithine phenylacetate) and 
placebo group during treatment infusion (5 first days) and follow-up period (FU, 28 days).
Placebo
n = 18 patients, 
n (%) infusion/FU
OP
n = 20 patients, n 
(%) infusion/FU
Organ system preferred term,
AE reported in at least in 5% patients
 
Investigators  
 Hypokalemia 1 (5.5) | 1/0 9 (45) | 7/2
 Hyponatremia 3 (16.7) | 3/0 2 (10) | 2/0
 Alkaline phosphatase increased 0 2 (10) | 0/2
Gastrointestinal disorders  
 Abdominal pain 3 (16.7) | 2/1 1 (5) | 0/1
 Diarrhoea 2 (11.1) | 1/1 1 (5) | 0/1
 Nausea 0 2 (10) | 2/0
Metabolism and nutrition disorders  
 Hyperglycemia 5 (27.8) | 5/0 8 (40) | 7/1
 Asthenia 3 (16.7) | 0/3 0
 Hypocalcemia 2 (11.1) | 2/0 0
Blood and lymphatic system disorders  
 Leukopenia 2 (11.1) | 1/1 1 (5)|1/0
 Lymphopenia 3 (16.7) | 2/1 0
 Neutropenia 1 (5.5) | 1/0 3 (15) | 3/0
Nervous system disorders  
 Dizziness 2 (11.1) | 1/1 0
Musculoskeletal disorders  
 Cramps 0 2 (10) | 0/2
Vascular disorders  
 Hypertension 2 (11.1) | 2/0 0
General disorders and administration-site conditions  
 Pyrexia 6 (33.3) | 2/4 3 (15) | 1/2
Psychiatric disorders  
 Anxiety 0 2 (10) | 1/1
Cirrhosis related  
 Ascites 2 (11.1) | 1/1 0
 Edemas 2 (11.1) | 1/1 1 (5) | 1/0
Any SAE  
Procedural complication  
 Hemorrhagic shock post TIPS 0 1 (5) | 0/1
 Upper-gastrointestinal hemorrhage 1 (5.5) | 0/1 2 (10) | 0/1
Cirrhosis related  
 Hepatic encephalopathy 0 1 (5) | 0/1
Nervous system disorders  
 Seizures due to cerebellar hemorrhage 1 (5.5) | 0/1 0
 Subdural hematoma 1 (5.5) | 0/1 0
Infections  
 Respiratory-tract infection 1 (5.5) | 0/1 1 (5) | 0/1
Blood and lymphatic-system disorders  
 Neutropenia 0 1* (5) | 1/0
AE, adverse event; SAE, severe adverse event; TIPS; transyugular porto-systemic shunt; FU, follow up; OP, ornithyne 
phenylactetate.
*Causality relationship between study medication and SAE was not established.
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suggesting not only the relevance of sample pro-
cessing, but the participation of genetic factors, 
such as the variability in the glutaminase gene 
[Romero-Gomez et al. 2010].
It is important to emphasize that the mean plasma 
concentration of PA achieved in our treated 
patients [maximum plasma PA level of 24.7 µg/ml 
at 36 hours of infusion (181 µmol/l), Table 3] is 
much lower than the concentrations obtained with 
similar therapies, such as glycerol phenylbutyrate 
(Ravicti ®) (Cmin: 84.4 µg/ml–Cmax: 292 µg/ml) 
[Ghabril et  al. 2013; Hyperion Therapeutics, 
2014] or sodium phenylacetate (Ammonul ®), 
(Cmin: 120 µg/ml–Cmax: 4652 µg/ml) [Food and 
Drug Administration, 2005]. We hypothesize that 
higher doses of OP, ranging from 15 to 20 g daily, 
would obtain higher plasma PA levels and there-
fore achieve a higher drop in plasma ammonia, to 
levels that have been historically associated with a 
low incidence of HE. These higher doses of OP 
should be probably applied to Child–Pugh A and 
B patients, since in our subgroup analysis, OP 
appeared to have a higher effect in Child–Pugh C 
patients with the current dose of 10 g/day. In addi-
tion, data from other studies indicate that Child–
Pugh C patients have higher exposure to PA than 
Child–Pugh A and B patients [Ghabril et al. 2013; 
McGuire et  al. 2010; Hyperion Therapeutics, 
2014]; the efficacy of higher doses of OP should 
be confirmed in future studies.
The total number of patients included in our 
study (38 patients) was calculated to detect a dif-
ference of 25 ± 25 (SD) μmol/l in the mean 
ammonia average between the two groups at 24 
hours. This calculation was based in the results of 
our pilot study [Ventura-Cots et al. 2013], where 
the decrease of plasma ammonia during the first 
24 hours in the treated group was compared with 
a historical cohort of 17 patients who exhibited a 
steady state of plasma ammonia during the first 
24 hours; this steady state was not observed in the 
placebo group of the present study. This fact has 
been critical to determine the lack of power in the 
present study to achieve the main objective.
The decrease of plasma glutamine concentration 
during time, as well as the increased in PAGN 
detected in urine, confirms the proposed mecha-
nism of action (combining glutamine to PA and 
enhancing urinary excretion). OP is a new drug 
that acts by providing an alternate pathway for 
ammonia removal in the form of urinary PAGN 
[Jalan et al. 2007]. In our study, the recovery of 
as much as 87% PA administered as urinary 
PAGN indicates that most of the drug is metabo-
lized and participates in ammonia removal. The 
plasma amino-acid profile of the OP-group 
patients also seems to support the existence of 
other ammonia-removal pathways promoted by 
OP and previously described in preclinical stud-
ies, such as the combination with glycine and its 
consequent decrease in plasma, followed by their 
elimination as phenylacetylglycine in urine 
[Kristiansen et al. 2014]. This hypothesis has not 
been confirmed in our study, since the urinary 
determination of phenylacetylglycine was not 
carried out.
Our trial had a similar incidence of HE episodes 
between both groups at baseline, during infusion 
and during follow up. Taking into account the 
incidence of HE during cirrhosis decompensation 
(16–21%) [EASL, 2010] and the sample size of 
our study (n = 38), differences in the incidence of 
HE were not expected. We did not observe sig-
nificant differences in baseline and follow-up 
Table 5. Total number of adverse events with grading and presentation time in treated (ornithine 
phenylacetate) and placebo patients.
Severity Infusion
(70)
Follow up
(53)
Total
(123)
Placebo
n (%)
OP
n (%)
Placebo
n (%)
OP
n (%)
Placebo
n (%)
OP
n (%)
40 (100%) 30 (100%) 28 (100%) 25 (100%) 68 (100%) 55 (100%)
Mild 29 (72.5%) 21 (70%) 22 (78.5%) 12 (48%) 51 (72.8%) 33 (55.9%)
Moderate 9 (22.5%) 8 (26.6%) 4 (14.2%) 8 (32%) 13 (18.5%) 16 (27.1%)
Severe 2 (5%) 1 (3.3%) 2 (7.1%) 5 (20%) 4 (5.7%) 6 (10.1%)
OP, ornithyne phenylactetate.
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ammonia levels in patients with HE, treated with 
OP or placebo.
The study confirms that OP, at the present dose, 
is a well-tolerated drug, even in decompensated 
cirrhotic patients. The incidence of adverse events 
and severe adverse events was the same in both 
groups, and it is important to underline that most 
of the adverse events recorded in both groups 
developed during the follow-up period, after drug 
infusion.
OP appears to be a well tolerated and promising 
drug for the treatment of ammonia-related com-
plications of cirrhosis, even in patients with poor 
liver function. The current study did not achieve 
the primary objective, but this was probably due 
to individual variability, a small number of 
patients included and mainly, too low a dose of 
OP administered. On the other hand, the consist-
ent decrease in ammonia levels during therapy in 
the treated group and the safety profile of OP 
indicate that with higher doses, especially in 
Child–Pugh A and B patients, a clinical effect will 
probably be achieved.
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